A carregar...
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
BACKGROUND: In locally advanced Non-Small-Cell Lung Cancer (LA-NSCLC) patients treated with chemoradiotherapy (CRT), optimal surrogate endpoint for cure has not been fully investigated. METHODS: The clinical records of LA-NSCLC patients treated with concurrent CRT at Shizuoka Cancer Center between S...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3901557/ https://ncbi.nlm.nih.gov/pubmed/24422706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-18 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|